MedTrace Logo

Extract of Ginkgo Biloba and Tardive Dyskinesia

NCT00672373 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2008-05-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether Extract of Ginkgo Biloba is effective in the treatment on Tardive dyskinesia

Conditions

Interventions

DRUG

Extract of Ginkgo Biloba (EGb-761 capsules)

EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.

DRUG

Placebo

Wheat flour placebo capsule,1 capsule tid, po,12 weeks

Sponsors & Collaborators

  • Peking University

    collaborator OTHER

  • Beijing HuiLongGuan Hospital

    lead OTHER

Principal Investigators

  • Yunlong Tan, Phd · Beijing HuiLongGuan Hospital

  • Dongfeng Zhou, Professor · Institute of mental health, Peking University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2007-05-31
Completion
2007-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00672373 on ClinicalTrials.gov